Update on Transplant in ALL

For many years, the use of blood and marrow transplant for adult patients with acute lymphoblastic leukemia (ALL) was primarily reserved for high-risk patients defined as those with a high white blood count, adverse cytogenetics, older age, and a delay in achieving remission. The landmark MRC UKALL XII/ECOG E2993 clinical trial also showed that patients with standard-risk ALL benefitted from allogeneic transplant in an intent-to-treat analysis.1
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research